MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage gene therapy company, announced a financing agreement with affiliates of Perceptive Advisors for up to US$100 million, including US$75 million upon closing, for the continued development of the company’s clinical-stage product candidates, preclinical programs and technology platforms, and for other general corporate purposes; the transaction involved work in the United States, United Kingdom, Ireland, and the Cayman Islands.

Latham & Watkins LLP represented MeiraGTx in the secured growth financing with a US finance team led by Bay Area partner Haim Zaltzman, with Bay Area associate Trevor Church and Austin associate Erin Cusenbary. Advice was also provided on US tax matters by Century City partner Sam Weiner, with Houston associate Mike Rowe; on UK tax matters by London partner Karl Mah, with London associates Sam Duncan and Lina Le Roux; on US corporate matters by New York partners Keith Halverstam and Ellen Smiley and Boston partner Peter Handrinos, with New York associates Danny Shulman, Jamie Conn, and Alyssa Fox, and Century City associate Kate Pritchard; on UK corporate matters by London associate Nick Fisher; on US regulatory matters by Washington, D.C. partner Elizabeth Richards and Bay Area counsel Betty Pang, with Washington, D.C. associate Nathan Beaton; on EU regulatory matters by Paris partner Eveline Van Keymeulen, with Paris associate Jeanne Fabre; on US intellectual property matters by Bay Area partner Chris Hazuka, with New York associate Arun Mohan, on US employee benefits and compensation matters by Washington, D.C. Partner Matthew Conway, with Washington, D.C. associate Marysia Mullen; on UK finance matters by London associates Lucy Hartland, Calvin Ng, and Angus Hortop; and on UK real estate matters by London partner Quentin Gwyer and London counsel Michael Beanland.